“…Prostate-specific antigen (PSA) has lately replaced prostatic acid phosphatase as the predominant tumour marker in prostate cancer (PC) [1], For all practical pur poses, PSA is exclusively produced by the prostatic epi thelial cells, both benign and most malignant cells [2], In benign conditions, the serum levels are usually low but a correlation between PSA and prostate volume has been found in patients with benign prostatic hyperplasia [3,4], Among patients with PC, the serum levels are usually higher. Also, in malignant disease there is a correlation between tumour burden and PSA, both in patients with whether PSA after hormonal treatment actually reflects the true tumour situation [10,11].…”